skip to content
Intravenous ketamine for the treatment of mental health disorders : a review of clinical effectiveness and guidelines Preview this item
ClosePreview this item
Checking...

Intravenous ketamine for the treatment of mental health disorders : a review of clinical effectiveness and guidelines

Author: Canadian Agency for Drugs and Technology in Health,
Publisher: Ottawa, Ontario : Canadian Agency for Drugs and Technology in Health, Beaconsfield, Quebec : Canadian Electronic Library, 2014. 2014.
Series: Rapid response report.
Edition/Format:   eBook : Document : EnglishView all editions and formats
Database:WorldCat
Summary:
Mental health disorders include anxiety, mood, and personality disorders. In any given year, one in five people in Canada experiences a mental health problem or illness, with a cost to the economy of well in excess of $50 billion. For the purposes of this paper, the focus will be on major depressive disorder (MDD), post-traumatic stress disorder (PTSD) and suicidal ideation. There are many issues with current  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

 

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Genre/Form: Electronic books
Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Canadian Agency for Drugs and Technology in Health,
OCLC Number: 896861422
Notes: "20 August 2014".
Description: 1 online resource (24 pages) : tables.
Series Title: Rapid response report.
Responsibility: prepared by Canadian Agency for Drugs and Technologies in Health.

Abstract:

Mental health disorders include anxiety, mood, and personality disorders. In any given year, one in five people in Canada experiences a mental health problem or illness, with a cost to the economy of well in excess of $50 billion. For the purposes of this paper, the focus will be on major depressive disorder (MDD), post-traumatic stress disorder (PTSD) and suicidal ideation. There are many issues with current pharmacotherapies used for mental health disorders. Some of these issues include the stigma of having a psychiatric illness, the side effects, and a perceived lack of response. A prior study in MDD patients found that roughly 30% of depressed patients discontinue medications within 30 days and more than 40% discontinue within 90 days making adherence a large issue. Clinical practice guidelines recommend a 6 to 12 month trial to adequately assess efficacy but due to these issues and a delayed onset of action, current pharmacotherapies are not an ideal in treatment option for acute and chronic episodes of mental health disorder. Ketamine emerged as a novel treatment for certain mental health disorders in 2000 when Berman et al. published a seven patient RCT of intravenous (IV) ketamine compared to a saline placebo showing a reduction in the Hamilton Depression Rating Scale (Ham-D). Given the lack of direction from major psychiatric associations, the utility of ketamine for certain mental health disorders is uncertain. The purpose of this report is to review the clinical effectiveness of intravenous ketamine for the treatment of depression, PTSD, and suicidal ideation, as well as the evidence-based guidelines for its use in these conditions.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/896861422> # Intravenous ketamine for the treatment of mental health disorders : a review of clinical effectiveness and guidelines
    a schema:Book, schema:MediaObject, schema:CreativeWork ;
   library:oclcnum "896861422" ;
   library:placeOfPublication <http://id.loc.gov/vocabulary/countries/onc> ;
   schema:about <http://experiment.worldcat.org/entity/work/data/2233619536#Topic/stress_disorders_post_traumatic_therapy> ; # Stress Disorders, Post-Traumatic--therapy
   schema:about <http://experiment.worldcat.org/entity/work/data/2233619536#Topic/suicidal_ideation> ; # Suicidal Ideation
   schema:about <http://experiment.worldcat.org/entity/work/data/2233619536#Topic/depression_mental_chemotherapy> ; # Depression, Mental--Chemotherapy
   schema:about <http://dewey.info/class/615.78/e23/> ;
   schema:about <http://experiment.worldcat.org/entity/work/data/2233619536#Topic/suicidal_behavior_chemotherapy> ; # Suicidal behavior--Chemotherapy
   schema:about <http://experiment.worldcat.org/entity/work/data/2233619536#Topic/depression_therapy> ; # Depression--therapy
   schema:about <http://experiment.worldcat.org/entity/work/data/2233619536#Topic/post_traumatic_stress_disorder_chemotherapy> ; # Post-traumatic stress disorder--Chemotherapy
   schema:about <http://experiment.worldcat.org/entity/work/data/2233619536#Topic/ketamine_therapeutic_use> ; # Ketamine--therapeutic use
   schema:author <http://experiment.worldcat.org/entity/work/data/2233619536#Organization/canadian_agency_for_drugs_and_technology_in_health> ; # Canadian Agency for Drugs and Technology in Health,
   schema:bookFormat schema:EBook ;
   schema:datePublished "2014" ;
   schema:description "Mental health disorders include anxiety, mood, and personality disorders. In any given year, one in five people in Canada experiences a mental health problem or illness, with a cost to the economy of well in excess of $50 billion. For the purposes of this paper, the focus will be on major depressive disorder (MDD), post-traumatic stress disorder (PTSD) and suicidal ideation. There are many issues with current pharmacotherapies used for mental health disorders. Some of these issues include the stigma of having a psychiatric illness, the side effects, and a perceived lack of response. A prior study in MDD patients found that roughly 30% of depressed patients discontinue medications within 30 days and more than 40% discontinue within 90 days making adherence a large issue. Clinical practice guidelines recommend a 6 to 12 month trial to adequately assess efficacy but due to these issues and a delayed onset of action, current pharmacotherapies are not an ideal in treatment option for acute and chronic episodes of mental health disorder. Ketamine emerged as a novel treatment for certain mental health disorders in 2000 when Berman et al. published a seven patient RCT of intravenous (IV) ketamine compared to a saline placebo showing a reduction in the Hamilton Depression Rating Scale (Ham-D). Given the lack of direction from major psychiatric associations, the utility of ketamine for certain mental health disorders is uncertain. The purpose of this report is to review the clinical effectiveness of intravenous ketamine for the treatment of depression, PTSD, and suicidal ideation, as well as the evidence-based guidelines for its use in these conditions."@en ;
   schema:exampleOfWork <http://worldcat.org/entity/work/id/2233619536> ;
   schema:genre "Electronic books"@en ;
   schema:inLanguage "en" ;
   schema:isPartOf <http://experiment.worldcat.org/entity/work/data/2233619536#Series/rapid_response_report_summary_with_critical_appraisal> ; # Rapid response report, summary with critical appraisal
   schema:isPartOf <http://experiment.worldcat.org/entity/work/data/2233619536#Series/rapid_response_report> ; # Rapid response report.
   schema:name "Intravenous ketamine for the treatment of mental health disorders : a review of clinical effectiveness and guidelines"@en ;
   schema:productID "896861422" ;
   schema:publisher <http://experiment.worldcat.org/entity/work/data/2233619536#Organization/canadian_agency_for_drugs_and_technology_in_health> ; # Canadian Agency for Drugs and Technology in Health,
   schema:url <http://alltitles.ebrary.com/Doc?id=10943187> ;
   wdrs:describedby <http://www.worldcat.org/title/-/oclc/896861422> ;
    .


Related Entities

<http://alltitles.ebrary.com/Doc?id=10943187>
   rdfs:comment "An electronic book accessible through the World Wide Web; click to view" ;
    .

<http://experiment.worldcat.org/entity/work/data/2233619536#Organization/canadian_agency_for_drugs_and_technology_in_health> # Canadian Agency for Drugs and Technology in Health,
    a schema:Organization ;
   schema:name "Canadian Agency for Drugs and Technology in Health," ;
    .

<http://experiment.worldcat.org/entity/work/data/2233619536#Series/rapid_response_report> # Rapid response report.
    a bgn:PublicationSeries ;
   schema:hasPart <http://www.worldcat.org/oclc/896861422> ; # Intravenous ketamine for the treatment of mental health disorders : a review of clinical effectiveness and guidelines
   schema:name "Rapid response report." ;
    .

<http://experiment.worldcat.org/entity/work/data/2233619536#Series/rapid_response_report_summary_with_critical_appraisal> # Rapid response report, summary with critical appraisal
    a bgn:PublicationSeries ;
   schema:hasPart <http://www.worldcat.org/oclc/896861422> ; # Intravenous ketamine for the treatment of mental health disorders : a review of clinical effectiveness and guidelines
   schema:name "Rapid response report, summary with critical appraisal" ;
    .

<http://experiment.worldcat.org/entity/work/data/2233619536#Topic/depression_mental_chemotherapy> # Depression, Mental--Chemotherapy
    a schema:Intangible ;
   schema:name "Depression, Mental--Chemotherapy"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2233619536#Topic/depression_therapy> # Depression--therapy
    a schema:Intangible ;
   schema:name "Depression--therapy"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2233619536#Topic/ketamine_therapeutic_use> # Ketamine--therapeutic use
    a schema:Intangible ;
   schema:name "Ketamine--therapeutic use"@en ;
   schema:name "Ketamine--Therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2233619536#Topic/post_traumatic_stress_disorder_chemotherapy> # Post-traumatic stress disorder--Chemotherapy
    a schema:Intangible ;
   schema:name "Post-traumatic stress disorder--Chemotherapy"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2233619536#Topic/stress_disorders_post_traumatic_therapy> # Stress Disorders, Post-Traumatic--therapy
    a schema:Intangible ;
   schema:name "Stress Disorders, Post-Traumatic--therapy"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2233619536#Topic/suicidal_behavior_chemotherapy> # Suicidal behavior--Chemotherapy
    a schema:Intangible ;
   schema:name "Suicidal behavior--Chemotherapy"@en ;
    .

<http://www.worldcat.org/title/-/oclc/896861422>
    a genont:InformationResource, genont:ContentTypeGenericResource ;
   schema:about <http://www.worldcat.org/oclc/896861422> ; # Intravenous ketamine for the treatment of mental health disorders : a review of clinical effectiveness and guidelines
   schema:dateModified "2017-04-01" ;
   void:inDataset <http://purl.oclc.org/dataset/WorldCat> ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.